SOUTH SAN FRANCISCO, Calif.,
May 31, 2019 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Dean Schorno, the company's
chief financial officer, is scheduled to present a company overview
at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2:30pm EDT.
To access the live webcast of the presentation or the subsequent
archived recording, log on to www.rigel.com. Please connect to
Rigel's website several minutes prior to the start of the live
webcast to ensure adequate time for any software download that may
be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is TAVALISSE®
(fostamatinib disodium hexahydrate), the only oral spleen tyrosine
kinase (SYK) inhibitor, for the treatment of adult patients with
chronic immune thrombocytopenia who have had an insufficient
response to a previous treatment. Rigel's clinical programs include
a Phase 3 study of TAVALISSE in warm autoimmune hemolytic anemia
(AIHA) and a Phase 1 study of R835, a proprietary molecule from its
interleukin receptor associated kinase (IRAK) program. In addition,
Rigel has product candidates in clinical development with partners
BerGenBio ASA, Daiichi Sankyo, Aclaris Therapeutics, and
AstraZeneca.
Please see www.TAVALISSE.com for full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2019-healthcare-conference-300859668.html
SOURCE Rigel Pharmaceuticals, Inc.